-
Mashup Score: 0Meeting Patient Needs: Innovative Catheter Packaging & Technology - Diane Newman & Don Darais - 2 year(s) ago
During this presentation, Diane Newman and Don Darais address the importance of meeting the needs of patients requiring catheterization, such as those with urinary incontinence or retention. In doing so, they showcase the packaging of GentleCath™ and Cure Medical products, highlighting important information for prescribing and using the products. Don Darais introduces the GentleCath™ Glide, a…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Sam Chang and Karan Jatwani discuss a study looking at the impact of neoadjuvant or adjuvant chemotherapy for patients with invasive disease, T2 disease, and the role of nephroureterectomy and how these treatments may impact findings. The study analyzed the NCDB database from 2004 to 2018 and found that neoadjuvant chemotherapy use was associated with a significantly improved overall survival…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Understanding Erectile Dysfunction: Patient Education and Personalized Treatment - Jeffrey Albaugh - 2 year(s) ago
Diane Newman dialogues with Jeff Albaugh to discuss Albaugh’s 30-year experience, his freely accessible guide for men with erectile dysfunction, and the significant role patient narratives and research play in making informed choices. Focusing on prostate cancer treatments, they delve into the effects on erectile function and recovery timeline. They explore different treatments, emphasizing the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the ARASENS Trial - Karim Fizazi - 2 year(s) ago
Alicia Morgans and Karim Fizazi discuss the ARASENS data and how it relates to whether patients with high-volume or low-volume metastatic castration-sensitive disease should be treated differently with systemic treatments. They explain that while historically, CHAARTED showed benefits in high-volume but not low-volume disease, STAMPEDE showed benefits for all patients regardless of volume. The…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 8Hospital Anxiety and Depression Scale (HADS) Score Trends Among Testicular Cancer Survivors: a Longitudinal Study - Khalid Alkhatib - 2 year(s) ago
Zach Klaassen hosts Khalid Alkhatib to discuss the mental health of testicular cancer patients. Dr. Alkhatib shares findings from his study, explaining that the disease impacts a younger demographic, making these patients more susceptible to anxiety and depression. The research revealed that the patients’ anxiety and depression levels did not improve over time after active treatment, contrary…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Hospital anxiety and depression scale (HADS) score trends among #TesticularCancer survivors: a longitudinal study. @Khalid_Alkhatib @PennUrology joins @zklaassen_md @GACancerCenter in this discussion on the mental health of testicular cancer patients > https://t.co/fzd0j5x1ki https://t.co/uqwFqznIXt
-
-
Mashup Score: 0
Sam Chang is joined in conversation by Gopa Iyer, discussing an article in European Urology that examines the predictive nature of FGFR3 wild-type versus mutant-type and its impact on patient response to perioperative chemotherapy in urothelial carcinoma. The study sought to evaluate the association between FGFR3 alterations and response to platinum-based chemotherapy, both in the perioperative…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0CaboPoint Study: Cabozantinib After Checkpoint Inhibitor Therapy in Patients with Advanced Renal Cell Carcinoma - Laurence Albiges - 2 year(s) ago
Laurence Albiges joins Pedro Barata to discuss the CaboPoint study, a clinical trial designed to examine the question of activity and safety of cabozantinib single agent in patients who failed first-line combination therapy for advanced renal cell carcinoma (aRCC). The study has two subgroups – Cohort A and Cohort B. Cohort A is the activity of cabozantinib after nivolumab/pembrolizumab, and…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Exploring Mentorship and Coaching in Urology: Insights and Strategies for Overcoming Burnout - Angie Smith - 2 year(s) ago
In a UroToday discussion, Angie Smith and Zach Klaassen discuss mentorship and coaching in urology, highlighting the significance of having multiple mentors and the notion that everyone can act as both a mentor and a mentee. Dr. Smith defines mentorship as the presence of an individual in one’s life who offers career guidance, while coaching is where you have a relationship with somebody who is…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Revolutionizing Urodynamics: Uromonitor's Comfortable, Real-Life Bladder Pressure Tracking - Diane Newman & Howard Goldman - 2 year(s) ago
Diane Newman engages in a discussion with Howard Goldman on the Uromonitor, a non-invasive urodynamic device designed to measure bladder pressures in a more comfortable, natural setting. This innovative device, developed in partnership with Bright Urology and the Cleveland Clinic, is placed in the bladder and allows patients to move freely without external catheters. The Uromonitor, with its…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Revolutionizing #urodynamics: @Uromonitor's comfortable, real-life #bladder pressure tracking. @DrDianeNewman is joined by Howard Goldman, MD, FACS @CleClinicUro to discuss this innovative device allowing pts to move freely without external catheters > https://t.co/mCXPquXUU1 https://t.co/PJ8SFhb5I2
-
-
Mashup Score: 0Combining CG0070 Adenovirus Vector with Immune Checkpoint Blockade: Promising Results for BCG Unresponsive Bladder Cancer Patients - Roger Li - 2 year(s) ago
Roger Li joins Ashish Kamat to discuss the CG0070 adenovirus vector and its potential use in combination with immune checkpoint blockade for patients with BCG unresponsive bladder cancer. The combination therapy has shown promising preliminary results, with 20 out of 22 patients achieving a complete response at three months and six out of eight patients maintaining a complete response at 12…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
Meeting patient needs: Innovative #Catheter packaging & technology. @DrDianeNewman @PennMedicine & Don Darais @Convatec highlight @GentleCath_US & @CureNationUSA products and important information for prescription and use. #WatchNow on UroToday > https://t.co/j4aaszuQS2 https://t.co/mZr84mbWD3